Over the last 20 years, alpha-adrenoceptor antagonists have become the primary first-line therapy for lower urinary tract symptoms related to benign prostatic hyperplasia (LUTS/BPH). Marco Caine was the first to popularize this class of medications; however, the nonselective alpha-1 and alpha-2 adrenoceptor antagonist phenoxybenzamine showed efficacy but very poor tolerability because of orthostatic- and dizziness-related side effects. Subsequently, usage of this class of medications increased with the advent of the long acting alpha-1 selective antagonists, terazosin, and doxazosin; however, these agents still had significant 10%-20% incidence of dizziness-related side effects. The addition of the long-acting alpha-1 A selective antagonist tamsulosin, which did nor affect blood pressure and had a lower side effect profile, cemented the position and role of alpha-antagonists as the primary therapy for LUTS/BPH.
展开▼
机译：在过去的20年中，α-肾上腺素受体拮抗剂已成为治疗与良性前列腺增生（LUTS / BPH）相关的下尿路症状的主要一线治疗方法。 Marco Caine是第一个推广此类药物的人。然而，由于体位性和头晕相关的副作用，非选择性的α-1和α-2肾上腺素能受体拮抗剂苯氧基苯扎明显示出疗效，但耐受性非常差。随后，随着长效α-1选择性拮抗剂，特拉唑嗪和多沙唑嗪的出现，这类药物的使用有所增加。但是，这些药物仍具有明显的10％-20％的头晕相关副作用发生率。长效的α-1A选择性拮抗剂坦索罗辛（既不影响血压又无副作用）的加入巩固了α-拮抗剂作为LUTS / BPH的主要疗法的地位和作用。
展开▼
